On December 27th, Sansheng Guojian issued an announcement stating that the company received the "Notice of Drug Clinical Trial Approval" approved and issued by the State Food and Drug Administration, approving the company's bispecific antibody injection SSGJ-706 to develop in advanced solid tumors and recurrences.
An open, multi-center, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SSGJ-706 in subjects with refractory lymphoma.
The company will carry out relevant clinical trials in the near future
The current anti-PD1 monoclonal antibody/anti-PDL1 monoclonal antibody single agent and combination chemotherapy have shown superior efficacy than previous standard treatments in many tumor fields
However, PD1/PDL1 inhibitor monotherapy has a low response rate in some patients with advanced solid tumors or needs to be in people with high expression of PDL1 in order to obtain better therapeutic effects.
This makes it possible to learn from PD1/PDL1 inhibitor monotherapy.
The people who benefited are limited
In order to further strengthen the efficacy of immunotherapy, multiple therapies such as dual immune checkpoint inhibitor combination therapy continue to appear.
Studies have shown that dual antibody inhibitors that target two different targets at the same time have a good therapeutic effect and are compared with two single The incidence of adverse reactions of anti-combination drugs may be low
SSGJ-706 is a recombinant bispecific antibody developed by Sansheng Guojian using the bispecific antibody platform with independent intellectual property rights.
It can simultaneously bind two targets closely related to tumor immunosuppressive function, thereby more effectively promoting T cell activation and Proliferation, and further enhance its tumor killing activity
Its pharmacodynamic studies have confirmed the anti-tumor efficacy of SSGJ-706 in a variety of transplanted tumors
In addition, non-clinical research data suggest that SSGJ-706 has good safety and tolerability